The SHARP CRC Health Economics Study. Simulation of the preventable costs of oral corticosteroids in severe asthmatics in eleven European countries

<bold>Background:</bold> Severe asthmatics (SA) consume roughly 50% of the global asthma healthcare resources due to unscheduled visits, hospitalizations, therapy, and management of oral corticosteroid (OCS) adverse events (AEs). Biologics offer a route away from continuous OCS treatment. Guidelines discourage OCS usage, particularly if continuous and at high doses, due to increased risk of AEs. This study simulates the economic burden of OCS-related reversible AEs (hypertension, psychiatric conditions, sleep disorders, dyspepsia) in SA patients in 11 European countries over 10 years. <bold>Methods:</bold> From each National Health System perspective, a budget impact model simulated total AE costs in SA patients in many OCS-sparing scenarios. AE costs due to exclusive OCS use were compared to AE costs when a percentage of the patients annually stops OCS, and the rate of OCS-related AEs decreases. Epidemiological data, OCS related-AE prevalences, and costs were collected from the literature (biologic therapy not considered). <bold>Results:</bold> Figure shows the potential savings over 10 years among SA patients; AEs costs were calculated under three scenarios of change in health-status (onset or amelioration of AE) namely after 1/2/3 years. E.g: reducing OCS use by 75 % would spare 5.3 to 782 million € over 10 years. <fig><object-id>erj;64/suppl_68/PA1176/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Conclusion:</bold> Stopping OCS can lead to consistent AE savings in SA patients over the long-term.

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa1176
Citations
1
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.33
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The SHARP CRC Health Economics Study. Simulation of the preventable costs of oral corticosteroids in severe asthmatics in eleven European countries

Piotr Kuna, Anneke Ten Brinke, Liam Gabriel Heaney, Sabina Škrgat et al.
1 citations
Asthma and respiratory diseases
0.33
article

The SHARP CRC Health Economics Study. Simulation of the preventable costs of oral corticosteroids in severe asthmatics in eleven European countries

Piotr Kuna, Anneke Ten Brinke, Liam Gabriel Heaney, Sabina Škrgat, B. Mascialino, Aruna T. Bansal, Thomas Paulsson, Chiara Martinotti, Renaud Louis, Zsuzsanna Csoma, ARNAUD AB BOURDIN, Barbro Dahlén, Ratko Djukanović, Elisabeth H. Bel, Giacomo Matteo Bruno, Enrico Marco Heffler, David Ramos‐Barbón, Celeste Porsbjerg, Sergio Di Matteo
article en
1 citations

Abstract

<bold>Background:</bold> Severe asthmatics (SA) consume roughly 50% of the global asthma healthcare resources due to unscheduled visits, hospitalizations, therapy, and management of oral corticosteroid (OCS) adverse events (AEs). Biologics offer a route away from continuous OCS treatment. Guidelines discourage OCS usage, particularly if continuous and at high doses, due to increased risk of AEs. This study simulates the economic burden of OCS-related reversible AEs (hypertension, psychiatric conditions, sleep disorders, dyspepsia) in SA patients in 11 European countries over 10 years. <bold>Methods:</bold> From each National Health System perspective, a budget impact model simulated total AE costs in SA patients in many OCS-sparing scenarios. AE costs due to exclusive OCS use were compared to AE costs when a percentage of the patients annually stops OCS, and the rate of OCS-related AEs decreases. Epidemiological data, OCS related-AE prevalences, and costs were collected from the literature (biologic therapy not considered). <bold>Results:</bold> Figure shows the potential savings over 10 years among SA patients; AEs costs were calculated under three scenarios of change in health-status (onset or amelioration of AE) namely after 1/2/3 years. E.g: reducing OCS use by 75 % would spare 5.3 to 782 million € over 10 years. <fig><object-id>erj;64/suppl_68/PA1176/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Conclusion:</bold> Stopping OCS can lead to consistent AE savings in SA patients over the long-term.

University of Verona (IT), Queen's University Belfast (GB), Humanitas University (IT), University of Ljubljana (SI), University of Liège (BE), Université de Montpellier (FR), University of Pavia (IT), Hospital de Sant Pau (ES), Bispebjerg Hospital (DK), Medisch Centrum Leeuwarden (NL), University of Łódź (PL), Centre Hospitalier Universitaire de Montpellier (FR), Queens University (BD), Svenska Örtmedicinska Institute (SE), Oclaro (United Kingdom) (GB), NIHR Southampton Respiratory Biomedical Research Unit (GB), NIHR Southampton Biomedical Research Centre (GB), Medical University of Lodz (PL), Institut d'Anàlisi Econòmica (ES), GlaxoSmithKline (Italy) (IT), Országos Korányi Tbc és Pulmonológiai Intézet (HU), University of Amsterdam (NL)
Openalex Percentile: Top 36%
Asthma and respiratory diseases
0.33
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.